Medmira (PK) (USOTC:MMIRF)
Historical Stock Chart
From Jan 2020 to Jan 2025
MedMira Remains Number One in U.S. Hospitals For 2nd Year
2004 CDC Report Demonstrates Excellent Performance of MedMira's Rapid HIV Test
HALIFAX, Jan. 18 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through
diagnostic technology, announced today that the results of the 2004 U.S. CDC
(Centers for Disease Control and Prevention) HIV Rapid Testing performance
evaluation showed that MedMira's Reveal(TM) Rapid HIV-1 Antibody Test
(Reveal(TM)) remains the test of choice in U.S. hospitals for the second
consecutive year.
The 2004 CDC study asked participants to evaluate a panel of HIV-positive and
negative donor specimens, that were provided by the CDC, using the rapid HIV
test utilized at their facility. A total of 384 participating testing sites
took part in the study. The study results indicated that the accuracy of the
Reveal(TM) test with HIV-positive specimens was 99.6% (compared to the overall
study average of 99.4%) and 99.6% for HIV-negative specimens (compared to the
overall study average of 99.5%). Additionally, the percentage of participating
United States hospitals using MedMira's test increased from 48% to 51% from the
2003 survey (announced August 12, 2004.) The study also showed an increased use
of serum/plasma as the sample type of choice for testing by hospitals, with a
decrease in oral fluid samples. MedMira's Reveal(TM) is a serum/plasma rapid
HIV test.
"MedMira prides itself on the high quality and excellent performance of its
rapid testing platform," said Hermes Chan, President and COO of MedMira. "The
results of this CDC study confirm these performance standards and provide
further evidence of the growing demand for Reveal(TM) in the United States."
Chan continued, "We are confident that our test will remain the test of choice
for the United States hospital sector."
A complete copy of the report is available on the CDC website at:
http://www.phppo.cdc.gov/mpep/pdf/rapid/HIVRT0408.pdf
About MedMira
MedMira is the leading global manufacturer and marketer of in vitro flow-though
rapid diagnostic tests for the clinical laboratory market. MedMira's tests
provide reliable, rapid diagnosis in just 3 minutes for the detection of human
antibodies in human serum, plasma or whole blood for diseases such as HIV. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For
more information visit MedMira's website at http://www.medmira.com/.
MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available.
MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada with a representative
office in Beijing, China.
This news release contains forward-looking statements, which involve risk and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
DATASOURCE: MedMira Inc.
CONTACT: Investor Relations - Dr. James Smith: (902) 450-1588 or e-mail: